Fredun Pharmaceuticals Ltd - 539730 - Fund Raising By Issuance Of Debt Securities By Large Entities- Annual Disclosure
Pursuant to the SEBI Circular No.: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, regarding Fund Raising by Issuance of Debt Securities by Large Entities; this is to confirm that the Company does not fall in the criteria mentioned under the said Circular and therefore does not qualify as Large Corporate as on 31st March, 2023. Fredun Pharmaceuticals Ltd - 539730 - Fund Raising By Issuance Of Debt Securities By Large Entities- Initial.
Pursuant to the SEBI Circular No.: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, regarding Fund Raising by Issuance of Debt Securities by Large Entities; this is to confirm that the Company does not fall in the criteria mentioned under the said Circular and therefore does not qualify as Large Corporate as on 31st March, 2023. Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder Certificate dated April 03, 2023 received from the SEBI Registered Registrar and Share Transfer Agent (RTA) viz. Purva Sharegistry (India) Pvt. Ltd. for the quarter ended March 31, 2023. Fredun Pharmaceuticals Ltd - 539730 - Yearly Compliance Certificate Under Regulation 7(3) Of SEBI Listing Regulations, 2015
In Compliance to Regulation 7(3) of SEBI Listing Regulations, 2015; we furnish hereunder the Certificate, duly signed by the Company Secretary of Fredun Pharmaceuticals Limited and by the Compliance Officer of 'Purva Sharegistry (India) Private Ltd.', designated Share Transfer Agent of the Company for the year ended March 31, 2023. Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and "Code of Conduct for Prevention of Insider Trading" of Fredun Pharmaceuticals Limited, we wish to inform that the Trading Window for dealing in securities of Fredun Pharmaceuticals Limited (the 'Company') shall remain closed for the Designated Persons viz. Directors, identified Employees, KMPs, Promoter and Promoter Group of the Company including Immediate Relatives of the Designated Persons of the Company and its subsidiaries and for the Connected Persons commencing from 01st April, 2023 till the declaration of quarterly and annually Audited Financial Results (AFR) of the Company for the last quarter and year ended 31st March, 2023 and 48 hours thereafter. The date of the Board Meeting of the Company for declaration of Audited Financial Results (AFR) for the last quarter and year ended 31st March, 2023 will be intimated to you in due course of time. Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation. Fredun Pharmaceuticals Ltd - 539730 - Revised Financial Results For Quarter Ended December 31,2022
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 27th January, 2023 had considered and approved the following item: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 31st December, 2022 along with the Limited Review Report as issued by M/s. Savla & Associates, Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 2.00 P.M. and concluded at 08:00 P.M. Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 27Th January ,2023
Revised outcome of the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 27th January, 2023 had considered and approved the following item: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 31st December, 2022 along with the Limited Review Report as issued by M/s. Savla & Associates, Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 2.00 P.M. and concluded at 08:00 P.M. Fredun Pharmaceuticals Ltd - 539730 - Financial Results For Quarter Ended December 31,2022
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 27th January, 2023 had considered and approved the following item: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 31st December 2022 along with the Limited Review Report as issued by M/s. Savla & Associates, Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 2.00 P.M. and concluded at 08:00 P.M. Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 27th January, 2023 had considered and approved the following item: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 31st December 2022 along with the Limited Review Report as issued by M/s. Savla & Associates, Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 2.00 P.M. and concluded at 08:00 P.M.